[1] Sotorasib was the first-in-class KRAS inhibitor to reach the US and European market, which locks the KRAS mutated protein in its inactive state. Sotorasib pharmacological inhibition is restricted to the KRAS p.G12C mutation, which is found at a frequency of 14% in non-small cell lung cancer (NSCLC) tumors and varying frequencies in other tumors [2]. However, the prevalence varies according to ethnicity and other population characteristics, as seen with a lower 8% rate in Colombia, with important variations across regions [3]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.